Aravind Palraj/LinkedIn
Jul 7, 2026, 22:23
Aravind Palraj: Antiphospholipid Syndrome is not Just ‘Start Warfarin and Follow INR’
Aravind Palraj, Senior Resident in Clinical Immunology and Rheumatology at Madras Medical College, shared a post on X:
“Antiphospholipid Syndrome is not just ‘start warfarin and follow INR.’
Management depends on:
- Thrombosis type (arterial vs venous)
- Obstetric profile
- Antibody pattern (triple-positive risk)
- Recurrent events
Triple-positive APS – Avoid DOACs Recurrent arterial events – Consider higher INR target Catastrophic APS – Anticoagulation plus steroids plus PLEX plus IVIG APS care is risk-stratified medicine.”
Find more posts featuring Aravind Palraj on Hemostasis Today.
-
Jul 13, 2026, 13:57Heghine Khachatryan: The Diagnostic Dilemma of Non-Criteria Obstetric APS
-
Jul 13, 2026, 13:49Mitra Najafi: Translating Years of Innovation into Global Scientific Dialogue at ISTH 2026
-
Jul 13, 2026, 13:2810 Posts Not To Miss from ISTH 2026, Part 2
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology